■ CALCIPHYLAXIS RISK FACTORS
Calciphylaxis, also referred to as calcifi c uremic arteriolopathy, is a rare and often fatal condition in patients with end-stage renal disease who are on hemodialysis (1% to 4% of dialysis patients). [1] [2] [3] It is also seen in patients who have undergone renal transplant and in patients with chronic kidney disease who have a chronic infl ammatory disease or who have been exposed to corticosteroids or warfarin. However, it can also occur FIGURE 1. The patient presented with extensive necrotic, leathery, violaceous lesions on both calves that resembled eschar. Also noted were adjacent discrete focal violaceous lesions in evolution.
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in patients without chronic kidney disease or end-stage renal disease.
The term "calcifi c uremic arteriolopathy" is a misnomer, as this condition can occur in patients with normal renal function (nonuremic calciphylaxis). Also, despite what the term calciphylaxis implies, there is no systemic anaphylaxis. [3] [4] [5] Documented risk factors include obesity; female sex; use of warfarin, corticosteroids, or vitamin D analogues; low serum albumin; hypercoagulable states; hyperparathyroidism; alcoholic liver disease; elevated calcium-phosphorus product; infl ammation; connective tissue disease; and cancer. [4] [5] [6] ■ DIAGNOSTIC CLUES There are no strict guidelines for the diagnosis of calciphylaxis, and the exact pathophysiology of calciphylaxis is not understood. [1] [2] [3] [4] Ulceration is considered the clinical hallmark, but there are increasing reports of patients presenting with nonulcerated plaques, as in our patient. The literature suggests a mortality rate of 33% at 6 months in these patients, but ulceration increases the risk of death to over 80%, and sepsis is the leading cause of death. 7, 8 Histologic features identifi ed on full-thickness biopsy specimens are intravascular deposition of calcium in the media of the blood vessels, as well as fi brin thrombi formation, intimal proliferation, tissue necrosis, and resultant ischemia. However, as in our patient and as discussed below, the biopsy procedure can induce or exacerbate ulceration, increasing the risk of sepsis, and is thus controversial. 7 In the early stages, lesions of calciphylaxis are focal and appear as erythema or livedo reticularis with or without subcutaneous plaques or ulcers. As the disease progresses, the ischemic changes coalesce to form denser violaceous, painful, plaquelike subcutaneous nodules with eschar. In the advanced stages, the eschar or ulceration involves an extensive area.
Diagnosis in the early stages is challenging because of the focal nature of involvement. The differential diagnosis includes potentially fatal conditions such as systemic vasculitis, nephrogenic systemic fi brosis, pyoderma gangrenosum, gangrene from peripheral arterial disease, cholesterol embolization, warfarininduced necrosis, purpura fulminans, and oxalate vasculopathy. 
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In the advanced stages, the diagnosis of calciphylaxis is clinically more evident, and the differential diagnosis usually narrows. Well-demarcated, necrotic, indurated lesions that are bilateral in a patient with end-stage renal disease without shock makes the diagnosis very likely.
The dangers of biopsy
As seen in our patient, biopsy for histologic confi rmation of calciphylaxis can increase the risk of infection and sepsis. 7 Also, the effi cacy and clinical utility are uncertain because the quantity or depth of tissue obtained may not be enough for diagnosis. Deep incisional cutaneous biopsy is needed rather than punch biopsy to provide ample subcutaneous tissue for histologic study. 3 Further, the biopsy procedure induces ulceration in the region of the incision, increasing the risk of infection and poor healing and escalating the risk of sepsis and death. [7] [8] [9] Since extensive necrosis predisposes to a negative biopsy, a high clinical suspicion should drive early treatment of calciphylaxis. 10 Noninvasive imaging studies such as plain radiography and bone scintigraphy can aid the diagnosis by detecting moderate to severe soft-tissue vascular calcifi cation in these areas.
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■ DEBRIDEMENT IS CONTROVERSIAL Conservative measures are the mainstay of care and include dietary alterations, noncalcium and nonaluminum phosphate binders, and low-calcium bath dialysis. There is mounting evidence for the use of calcimimetics and sodium thiosulfate. 7, [12] [13] [14] The role of wound debridement is controversial, as concomitant poor peripheral vascular perfusion can delay wound healing and, if ulceration ensues, there is a dramatic escalation of mortality risk. The decision for wound debridement is determined case by case, based on an assessment of the comorbidities, vascular perfusion, and status of the eschar.
Extensive wound debridement should be considered immediately after biopsy or with any signs of ulceration or infection-this in addition to meticulous wound care, which will promote healing and prevent serious complications secondary to infection. 15 
■ A TEAM APPROACH IMPROVES OUTCOMES
A multidisciplinary approach involving surgeons, nephrologists, dermatologists, dermatopathologists, wound or burn care team, nutrition team, pain management team, and infectious disease team is important to improve outcomes. 7 Management mainly involves controlling pain; avoiding local trauma; treating and preventing infection; stopping causative agents such as warfarin and corticosteroids; intensive hemodialysis with an increase in both frequency and duration; intravenous sodium thiosulphate; non-calcium-phosphorus binders and cinacalcet in patients with elevated parathyroid hormone; and hyperbaric oxygen. [12] [13] [14] There are also reports of success with oral etidronate and intravenous pamidronate. 16, 17 ■ ■ REFERENCES
